Enteropathy‐associated T‐cell lymphoma: A population‐based cohort study on incidence, treatment, and outcome in the Netherlands

Enteropathy‐associated T‐cell lymphoma: A population‐based cohort study on incidence, treatment, and outcome in the Netherlands

Abstract Introduction Enteropathy‐associated T‐cell lymphoma (EATL) is a peripheral T‐cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended fo...

Full description

Saved in:
Bibliographic Details
Main Authors: Frederik O. Meeuwes, Mirian Brink, Wouter J. Plattel, Joost S. P. Vermaat, Marie José Kersten, Mariëlle Wondergem, Otto Visser, Marjolein W. M. van derPoel, Rimke Oostvogels, F. J. Sherida H. Woei‐A‐Jin, Lara Böhmer, Tjeerd J. F. Snijders, Gerwin A. Huls, Marcel Nijland
Format: Article
Language:English
Published: Wiley 2024-12-01
Series:eJHaem
Subjects:
ASCT
EATL
enteropathy‐associated T‐cell lymphoma
etoposide
outcome
Online Access:https://doi.org/10.1002/jha2.1049
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Introduction Enteropathy‐associated T‐cell lymphoma (EATL) is a peripheral T‐cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended for fit PTCL patients. The role of etoposide and ASCT in EATL is unclear. Methods This study reports the incidence, treatment, and outcome of EATL patients using the Netherlands Cancer Registry, with nationwide coverage of >95%. Results All patients diagnosed in 1989–2021 (n = 351, 77% treated) were identified (median age 67 years, 56% male, 50% limited stage). Time period analysis assessed trends in primary therapy and overall survival (OS). Treatment included chemotherapy (CT) (34%), surgery (18%), surgery and CT (19%) or CT followed by ASCT (7%). The 5‐year OS for treated patients with limited versus advanced stage was 19% and 9% respectively. The 2‐year OS improved over time (21%–33%, p = 0.06). Surgery only (hazard ratio [HR] 2.16; 95% confidence interval [CI] 1.55–3.01, p < 0.01) and advanced‐stage disease (HR 1.67; 95% CI 1.25–2.23, p = 0.01) were predictors of poor prognosis. ASCT (HR 0.31; 95% CI 0.18–0.56) was associated with improved OS. Conclusion There was no statistical difference in OS between patients treated with or without etoposide. Current first‐line treatment is ineffective.
ISSN:2688-6146

Similar Items